Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma

Archives of Dermatology

Volumn 148, Issue 11, 2012, Pages 1324-1325

  Chang, Anne Lynn S ^a   Oro, Anthony E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VISMODEGIB;

ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTINUOUS INFUSION; FOLLOW UP; HUMAN; LOCALLY ADVANCED BASAL CELL CARCINOMA; MEDICAL RECORD; METASTATIC BASAL CELL CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR GROWTH;

EID: 84869131318     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.2354     Document Type: Article

References (5)

1. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164-1172.
2. LoRusso PM, Rudin CM, Reddy JC, et al. Phase 1 trial of hedgehog pathway inhibitor vismodegib (GDC0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-2511.
3. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
4. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 2011;71(15):5057-5061.
5. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71(2):435-444.